Cabozantinib S-malate

苹果酸卡博替尼

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameCabozantinib S-malate
Drug Alias Name卡赞替尼Cabozantinibumcabozantinib卡波替尼卡博替尼苹果酸盐 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsTEK receptor tyrosine kinase antagonistsVascular endothelial growth factor receptor 1 antagonists +[13] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 2Vascular endothelial growth factor receptor 3 +[13] 
Therapy Area/IndicationsBone metastasesPancreatic neuroendocrine tumors (pNET)Medullary thyroid cancer (MTC) +[80] 
Global Approved IndicationsThyroid NeoplasmsCarcinoma, Renal CellCarcinoma, Neuroendocrine
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/11/29
Country/TerritoryCzechiaBelgiumCanada +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityDana-Farber Cancer InstituteIpsen +[27] 
Inactive CompaniesRadboud University Medical CenterJohannes Gutenberg-University MainzWeill Medical College of Cornell University +[13] 
Active IndicationsPancreatic neuroendocrine tumors (pNET)Medullary thyroid cancer (MTC)Neuroendocrine Carcinoma of Lung +[46] 
Inactive IndicationsBone metastasesBrain metastasesPoorly Differentiated Thyroid Gland Carcinoma +[34] 

Other Information

ATC CodeL01EX07
Related LinksWikipediaDrugBankKEGG